


Serbia

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009	2012	2015	2018
International units per capita	Factor VIII	1.44	▲ 1.98	▲ 2.02	▲ 3.34
	Factor IX	0.11	▲ 0.20	▲ 0.24	▲ 0.44
Organisation of care	Comprehensive Care Centres (CCC's)	No	No	▲ Yes	Yes
	Haemophilia Treatment Centres	Yes	Yes	Yes	Yes
	National Haemophilia Council or Co-ordinating Group	Yes	Yes	Yes	Yes
	Number of groups in decision-making on haemophilia care	0	▲ 3	3	3
	Number of groups choosing haemophilia treatment products	0	▲ 3	3	3
	National Tender for procurement of factor concentrates		Yes	Yes	Yes
Treatment regimens	Home Treatment	Yes	Yes	Yes	Yes
	% of people with haemophilia using home treatment	10-50%	10-50%	10-50%	▲ 76-100%
	Treatment delivered to the patient's home	No	No	No	No
	Prophylaxis treatment availability	Some	Some	Some	▲ Yes
	Children currently on prophylaxis (%)	1-25%	1-25%	▲ 51-75%	▲ 76-100%
	Adults currently on prophylaxis (%)	1-25%	1-25%	1-25%	▲ 26-50%
Access to specialist services	Access to ITI (% of people with inhibitors)	0	0	1-25%	▲ 51-75%
Access to specialist services	Emergency medicine and acute surgery		Yes	Yes	Yes
	Paediatrics		Yes	Yes	Yes
	Infectious disease specialists (especially HIV)		Yes	Yes	▼ Sometimes
	Hepatology		Sometimes	▲ Yes	▼ Sometimes
	Rheumatology		Sometimes	▲ Yes	▼ Sometimes
	Orthopaedics		Sometimes	▲ Yes	Yes
	Physiotherapy		Sometimes	▲ Yes	Yes
	Dentistry		Yes	Yes	Yes
	Obstetrics and Gynaecology		Sometimes	▲ Yes	▼ Sometimes
	Genetics		Sometimes	Sometimes	Sometimes
	Social and psychological support		Sometimes	Sometimes	Sometimes
	Pain management		Never	Never	▲ Sometimes
	General surgery		Yes	Yes	▼ Sometimes
Urology		Sometimes	▲ Yes	▼ Sometimes	
Share of Expected Bleeding Disorder Prevalence	Haemophilia A	55%	▲ 56%	▲ 62%	▲ 65%
	Haemophilia B	31%	▲ 31%	▲ 36%	▲ 40%
	von Willebrand Disease	3%	▼ 3%	▲ 4%	▲ 4%
Haemophilia replacement therapy	Pasma-derived factor concentrate	Always	Always	Always	Always
	Recombinant factor concentrate	Never	▲ Rarely	▲ Sometimes	▲ Always
	Plasma	Never	Never	▼ Rarely	▲ Never
	Cryoprecipitate	Never	Never	▼ Rarely	▲ Never
VWD replacement therapy	Plasma-derived factor concentrate		Always	Always	Always
	DDAVP		Rarely	Rarely	▲ Always
	Plasma		Never	▼ Rarely	▲ Never
	Cryoprecipitate		Never	▼ Rarely	▲ Never